Corvus Pharmaceuticals Says Updated Data From CPI-818 Phase 1/1B Trial In Solid & Hematological Cancers Continues To Demonstrate The Potential Of ITK Inhibition And Absolute Lymphocyte Count Biomarker In T Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Corvus Pharmaceuticals announced updated data from its CPI-818 Phase 1/1B trial in solid and hematological cancers, demonstrating the potential of ITK inhibition and absolute lymphocyte count biomarker in T cell lymphoma.
June 15, 2023 | 11:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corvus Pharmaceuticals' updated data from the CPI-818 Phase 1/1B trial demonstrates the potential of ITK inhibition in T cell lymphoma, which may positively impact the company's stock.
The updated data from the CPI-818 Phase 1/1B trial demonstrates the potential of ITK inhibition in T cell lymphoma, which is a positive development for Corvus Pharmaceuticals. This news may lead to increased investor interest and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100